top of page

OrbiMed's Carl Gordon shares his take on biotech's 2025 and what could be ahead for the sector in 2026

  • Dec 15, 2025
  • 1 min read

He discusses the causes of the rapid bounce biotech has witnessed over the last handful of months, his take on 2026, including the IPO environment, private vs public companies, areas of interest, and more.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page